¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Hepatitis A Inactivated/ Hepatitis B"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
¿µ¹® hepatitis ÇÑ±Û °£¿°
¼³¸í   
  °£¿¡ »ý±â´Â ¿°ÁõÀ» ÅëÆ²¾î À̸£´Â ¸». ¹ß¿­-Ȳ´Þ-Àü½Å±ÇÅÂ-¼ÒÈ­ Àå¾ÖÀÇ Áõ»óÀ» º¸À̴µ¥, ÁֵȠ¿øÀÎÀº À½½Ä¹°°ú Ç÷¾×À» ÅëÇÑ ¹ÙÀÌ·¯½º °¨¿°À̸砱נ¹Û¿¡ ¾à¹°, ¾ËÄÚ¿Ã, ¾Ë·¹¸£±â µîÀÌ ¿øÀÎÀΠ°Íµµ ÀÖ´Ù. ÀÌ °£¿°Àº ±× Áö¼Ó±â°£¿¡ µû¶ó¼­ ±Þ¼º°£¿°°ú ¸¸¼º°£¿°À¸·Î ³ª´©´Âµ¥, ¸¸¼º°£¿°Àº 6°³¿ù À̻󠰣¿°ÀÌ Áö¼ÓµÇ´Â °æ¿ì¸¦ ¸»ÇÏ°í ±Þ¼º°£¿°Àº 6°³¿ù ÀÌ»ó Áö¼ÓÇÏÁö ¸øÇϴ °æ¿ì¸¦ ¸»ÇÑ´Ù. ±Þ¼º°£¿°Àº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º-½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇϴ ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀÌ´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༱°£¿°(AÇü)°ú Ç÷û°£¿°(BÇü)ÀÇ µÎ Á¾·ù°¡ Àִµ¥, À̵éÀº ¸ðµÎ Àü¿°¼º ÁúȯÀÌÁö¸¸ °¨¿° °æ·Î´Â ´Ù¸£´Ù. °¨¿° °æ·Î·Î À¯Ç༱°£¿°¹ÙÀÌ·¯½º´Â Ç÷¾×-»ùâÀÚ¾×-´ëº¯ Áß¿¡¼­ Áõ¸íµÇ¹Ç·Î Àü¿°µÈ ¹°-À½½ÄÀ» ÅëÇÏ¿© °æ±¸°¨¿°µÇ°Å³ª È¯ÀÚ¿ÍÀÇ Á÷Á¢ Á¢ÃË¿¡ ÀÇÇØ¼­ °¨¿°µÈ´Ù. Ç÷û°£¿°Àº ¿À·ÎÁö ºñ°æ±¸Àû °¨¿°À¸·Î È¯ÀÚÀÇ Ç÷û, Ç÷¾×ÀÇ ÁÖ»ç, È¯ÀÚÀÇ Ç÷¾×¿¡ °¨¿°µÈ ÁÖ»ç±â µîÀ¸·Î °¨¿°µÈ´Ù. Àẹ±â´Â À¯Ç༺°£¿°ÀÌ 2~6ÁÖ°£À̰í, Ç÷û °£¿°Àº 6ÁÖ~6°³¿ù °¡·® µÈ´Ù. Ç÷û°£¿°Àº À¯ÇàÀÇ °èÀý-¿¬·É°ú´Â °ü°è°¡ ¾øÀ¸³ª, À¯Ç༺°£¿°Àº ÁַΠ°¡À»¿¡¼­ °Ü¿ï¿¡ °ÉÃÄ ¸¹°í Ã»¼Ò³â¿¡ ¸¹´Ù. Áõ¼¼´Â ¹ßº´Çϱâ 1ÁÖÀÏ ÀüºÎÅÍ ¿Â¸öÀÌ ³ë°ïÇÏ°í ½Ä¿åÀÌ ¶³¾îÁö¸ç µÎÅëÀÌ ÀÖ°í »óº¹ºÎ¿¡ ºÒÄè°¨ÀÌ »ý±â´Âµ¥, À¯Ç༺°£¿°¿¡¼­´Â È²´ÞÀÌ ³ªÅ¸³ª±â Àü¿¡ ¹ß¿­(38¡É ÀüÈÄ)ÀÌ ÀÖÀ» ¶§°¡ ¸¹°í ¼öÀÏ ÈÄ¿¡ ÇØ¿­µÈ´Ù. ¶Ç, °üÀý-Ç㸮°¡ ¾ÆÇà¶§µµ ÀÖ¾î Ã³À½¿¡´Â °¨±â·Î ¿ÀÀÎÇÒ ¶§°¡ ¸¹´Ù. Ç÷û°£¿°Àº ÀÌ·¯ÇÑ Ãʱâ Áõ¼¼°¡ °¡º±°í ¼­¼­È÷ ¹ßº´Çϴ °ÍÀÌ ¸¹´Ù. ÁÖÁõ¼¼´Â À§ÀåÁõ¼¼¿Í È²´ÞÀ̸ç, ½Ä¿åºÎÁø-±¸Åä-±¸¿ªÁú, »óº¹ºÎÀÇ µÐÅë µîÀÌ ÀϾ¸ç, ¹ßº´ ÈÄ 4~5ÀÏ¿¡ È²´ÞÀÌ ³ªÅ¸³­´Ù. È²´ÞÀº 1ÁÖÀÏÀ» ÀüÈÄÇÏ¿© ÃÖ°í¿¡ À̸£¸ç, ±× ÈÄ 1°³¿ù »çÀÌ¿¡ ¾ø¾îÁö¸é¼­ ´Ù¸¥ Áõ¼¼µµ ÁÁ¾ÆÁø´Ù. °æ°ú´Â ±Þ¼º°£¿°Àº ¾à 70%°¡ ´ë°³ 1~3°³¿ù À̳»¿¡ Ä¡À¯µÇÁö¸¸ »¡¸® Ä¡·áµÇÁö ¾Ê´Â °Í Áß 15%°¡ ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϸç, ±× ÀϺδ °£°æÈ­ÁõÀ¸·Î ÀÌÇàÇÑ´Ù. ±Þ¼º°£¿° Áß¿¡´Â ¶§·Î´Â 10ÀÏ À̳»¿¡ »ç¸ÁÇϴ Àü°Ý¼º°£¿°À̶ó°í Çϴ °Íµµ ÀÖ´Ù. º´ÀÇ Àüü °æ°ú ÁߠȲ´ÞÀÌ ³ªÅ¸³ªÁö ¾Ê´Â ¹«È²´Þ¼º °£¿°À̶ó°í Çϴ °Íµµ ÀÖ¾î. ¸¸¼º°£¿°À¸·Î ÀÌÇàÇϴ °Í¿¡´Â ÀÌ ¹«È²´Þ¼ºÀÌ ¸¹Àº °æÇâÀÌ ÀÖ´Ù. Ç÷û°£¿°µµ ¸¸¼ºÈ­Çϱ⠽±´Ù.
¿µ¹® acute hepatitis ÇÑ±Û ±Þ¼º°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º¿¡ ÀÇÇØ °£¿¡ »ý±â´Â ±Þ¼º¿°Áõ. ±Þ¼º°£¿°À̶õ °£¿°¹ÙÀÌ·¯½º(AÇü-BÇü-ºñAºñBÇü)¿¡ ÀÇÇØ¼­ °£¿¡ »ý±â´Â ±Þ¼º¿°ÁõÀ» º´¸íÀ¸·Î À̸£´Â ¸»·Î, À̴ ±× °¨¿°¾ç½Ä¿¡ ¼öÇ÷ ÈÄ¿¡ ¹ß»ýÇϴ ¼öÇ÷ÈÄ °£¿°°ú, °¨¿°°æ·Î¸¦ ¾Ë ¼ö ¾ø´Â »ê¹ß¼º°£¿° ¹× Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༱°£¿°ÀÇ ¼¼°¡Áö À¯ÇüÀ¸·Î ³ª´­ ¼ö ÀÖ´Ù. ¼öÇ÷ÈÄ °£¿°Àº ±× 95%°¡ ºñAºñBÇü°£¿°À̸砳ª¸ÓÁö°¡ BÇü °£¿°ÀÌ´Ù. »ê¹ß¼º °£¿°Àº AÇü °£¿°°ú BÇü °£¿°ÀÌ °¢°¢ 30%¸¦ ÀÌ·ç°í ³ª¸ÓÁö 40%´Â ºñAºñB°£¿°ÀÌ´Ù. Áý´ÜÀ¸·Î ¹ß»ýÇϴ À¯Ç༺°£¿°Àº °ÅÀǰ¡ AÇü°£¿°ÀÌÁö¸¸ ¶§·Î´Â ¿©±â¿¡ Æ÷ÇÔµÇÁö ¾ÊÀº ÇüÀÇ °£¿°ÀÏ °æ¿ìµµ ÀÖ´Ù. ±Þ¼º°£¿°ÀÇ Áõ¼¼´Â ¸ÕÀú ¸öÀÌ ³ª¸¥ÇØÁö°í ¿Â¸ö¿¡ ±ÇۨÀ̠ã¾Æ¿À¸ç Á¶±×¸¶ÇÑ ÀÏ¿¡µµ °ð ÇǷθ¦ ´À³¢°Ô µÈ´Ù. ±×¸®°í ½Ä¿åºÎÁø-¹ß¿­-±¸ÅäÁõ-º¹Åë-¼³»ç µî, °¨±â³ª ±Þ¼ºÀ§Àå¿°¿¡ °É·ÈÀ» ¶§¿Í °°Àº Áõ¼¼ µîÀÌ ³ªÅ¸³­´Ù. µÚÀ̾î È²´ÞÁõ¼¼¸¦ º¸À̴µ¥, À̶§´Â ÃʱâÀÇ Áõ¼¼°¡ ¾à°£ °¡º­¿öÁø °Íó·³ ´À²¸Áö´Â °ÍÀÌ º¸ÅëÀÌ´Ù. ±×·¯³ª È²´ÞÁõ¼¼°¡ ½ÉÇØÁö°í ÃʱâÀÇ Áõ¼¼µéÀÌ ´Ù½Ã ÁøÇàµÇ¸é À̶§´Â Àü°Ý¼º°£¿°ÀÌ µÉ À§ÇèÀÌ ÀÖ´Ù. °£¿° Áõ¼¼°¡ ½ÉÇÏÁö ¾Ê¾ÒÀ» °æ¿ì´Â È²´ÞÀÌ ´«¿¡ ¶çÁö ¾ÊÀº °æ¿ìµµ Àִµ¥ À̶§´Â ÁøÂûÀ» Çصµ °¨±â³ª ±Þ¼ºÀ§Ã¢ÀÚ¿°À¸·Î ÀÚÄ© ¿ÀÁøµÇ±â ½±´Ù. ¶Ç AÇü°£¿°Àº ¿­ÀÌ 38~39¡É±îÁö ¿À¸£°í Áõ¼¼°¡ °©Àڱ⠳ªÅ¸³ª´Â °ÍÀ̠Ư¡À̸砱޼ººñAºñBÇü°£¿°Àº Áõ¼¼°¡ ºñ±³Àû °¡º­¿î °ÍÀ̠Ư¡ÀÌ´Ù. ±Þ¼ºBÇü°£¿°ÀÇ Áõ¼¼´Â AÇü°£¿°°ú ±Þ¼ººñAºñBÇü°£¿°ÀÇ Áß°£ Á¤µµÀΠ°ÍÀÌ º¸ÅëÀÌ´Ù.
¿µ¹® chronic active hepatitis ÇÑ±Û ¸¸¼ºÈ°µ¿°£¿°
¼³¸í   
  BÇü °£¿°À̳ª ºñAÇü£­ºñBÇü °£¿°ÀÇ ¼Ó¹ßÁõÀ¸·Î ³ªÅ¸³ª´Â °£ÀÇ ¸¸¼º¿°ÁõÀÌ´Ù. °°Àº ÇüÅÂÀÇ º´ÀÌ ¼±Ãµ¼º ¶Ç´Â ÈÄõ°¨¸¶±Û·ÎºÒ¸°°áÇÌÁõÀ̳ª ¾î¶² Á¾·ùÀÇ ¾à¹° Åõ¿©¿¡ ¼ö¹ÝÇØ¼­ ³ªÅ¸³¯ ¼öµµ ÀÖ´Ù. Æ¯Â¡ÀûÀ¸·Î ¹®¸ÆºÎ¿¡ ÇüÁú¼¼Æ÷¿Í Å«Æ÷½Ä¼¼Æ÷ÀǠħÀ±, Á¶°¢±«»ç(°£¼Ò¿± ÁÖº¯ºÎ °£¼¼Æ÷ÀÇ ÆÄ±«) ¹× ¼¶À¯Áõ µîÀÇ Á¶Á÷¼Ò°ßÀ» ³ªÅ¸³½´Ù. º´ÀÇ °æ°ú´Â ¸Å¿ì ´Ù¾çÇϸç Àå±â°£ÀÇ ¹«Áõ»ó±â¸¦ º¸ÀÏ ¼öµµ ÀÖ°í ±× »çÀÌ »çÀÌ¿¡ È²´Þ, Àü½Å¼è¾à, ½Ä¿åºÎÁø ¹× ¹ß¿­ µîÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖÀ¸¸ç, ¶Ç ¹«¿ù°æÁõ, °üÀý¿°, ÇǺιßÁø, Ç÷°ü¿°, °©»ó»ù¿°, ÄáÆÏ»ç±¸Ã¼¿°, ±Ë¾ç¼º´ëÀå¿°, ½¦±×·»ÁõÈıº µî °£ ÀÌ¿ÜÀÇ Áõ»óÀÌ ³ªÅ¸³ª´Â ¼öµµ ÀÖ°í, °£°æÈ­Áõ°ú °£±â´É»ó½Ç·Î ÁøÇàµÇ´Â ¼öµµ ÀÖ´Ù. ÀÚ°¡¸é¿ª¸ÞÄ¿´ÏÁòÀÌ °ü¿©µÇ´Â °ÍÀ¸·Î ÃßÃøµÇ°í ÀÖ´Ù.
¿µ¹® fulminant hepatitis ÇÑ±Û Àü°Ý°£¿°
¼³¸í   
  ¹ÙÀÌ·¯½º °£¿°ÀÇ ÇÑ ÇüÀ¸·Î ±Þ¼º È²»öÀ§ÃàÁõÀ̶ó°íµµ ºÎ¸¥´Ù. °£¼¼Æ÷ÀÇ ´ëºÎºÐÀÌ ±«»ç»óÅ·ΠµÇ¸ç È¯Àڴ º¸Åë »ç¸ÁÇÑ´Ù. È²´ÞÀÌ ³ªÅ¸³ª±â ÀüºÎÅÍ À̹̠Áõ»óÀº ÇöÀúÈ÷ ÁøÇàÇÏ¿© È²´ÞÀÇ ÃâÇöµµ ºü¸£°í, ±Þ¼º ¹ß¿­À» ¼ö¹ÝÇϸç Á¡¸·À̳ª ÇÇÇÏÃâÇ÷À» º¼ ¼ö ÀÖ´Ù. °£ÀÇ ¾ÐÅëÀ» ¼ö¹ÝÇϴ ¼öµµ ÀÖ´Ù. À§Ãà¿¡ ÀÇÇÏ¿© °£Àº ÀÚÁÖ ÀÛ¾ÆÁø´Ù. ÃÖÈÄ¿¡´Â ÀǽÄÀå¾Ö¸¦ ÃÊ·¡ÇÏ¿© Á¹À½ÀÌ ¿À°í È¥¹Ì»óÅ·ΠµÇ¸ç °£¼ºÈ¥¼ö·Î ÁøÇàÇÏ¿© »ç¸ÁÇϰԠµÈ´Ù. Áõ»óÀÌ ½ÃÀ۵Ǿî 2~3ÁÖ ³»¿¡ °£³úº´Áõ±îÁö ÁøÇàÇϴ °£±â´É »ó½ÇÀ» Àü°Ý¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸£¸ç, ÁøÇà ¼Óµµ°¡ ºü¸£Áö ¾Ê¾Æ¼­ 3°³¿ù¿¡ À̸£·¯ °£±â´É»ó½Ç¿¡ ºüÁö´Â °ÍÀº ¾Æ±Þ¼º °£±â´É»ó½ÇÀ̶ó°í ºÎ¸¥´Ù. ¸ðµç °£¿° ¹ÙÀÌ·¯½º°¡ ¸ðµÎ ÀÏÀ¸Å°Áö´Â ¾Ê´Â´Ù. °£¿°A¹ÙÀÌ·¯½º¿Í °£¿°E¹ÙÀÌ·¯½º´Â º¸À¯ÀÚ »óųª ¸¸¼º °£¿°À» °ÅÀÇ ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. ±âŸ ´Ù¸¥ °¨¿° ¶Ç´Â ºñ°¨¿°¼º ¿øÀÎ, Æ¯È÷ ¾à¹°°ú µ¶¼Òµµ º»ÁúÀûÀ¸·Î µ¿ÀÏÇÑ ÁõÈĸ¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù. ±×·¯¹Ç·Î ¹ÙÀÌ·¯½º¼º °£¿°ÀÇ Áø´Ü°ú °¢ °£¿° ¹ÙÀÌ·¯½º¸¦ ±¸º°Çϴµ¥´Â Ç÷ûÇÐÀû °Ë»ç°¡ ÇʼöÀûÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivated serum
    ºñȰ¼ºÈ­Ç÷û
  • inactivated vaccine
    ºÒȰ¼ºÈ­¹é½Å, ºñµ¿È­¹é½Å
  • anicteric hepatitis
    ¹«È²´Þ°£¿°
  • autoimmune hepatitis
    ÀÚ°¡¸é¿ª°£¿°
  • acute hepatitis
    ±Þ¼º°£¿°
  • alcoholic hepatitis
    ¾ËÄڿ𣿰
  • amebic hepatitis
    ¾Æ¸Þ¹Ù°£¿°
  • cholangiolitic hepatitis
    ¾µ°³¼¼°ü¿°¼º°£¿°, ´ã¼¼°ü¿°¼º°£¿°
  • cholestatic hepatitis
    ¾µ°³ÁóÁ¤Ã¼°£¿°, ´ãÁóÁ¤Ã¼°£¿°
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • chronic hepatitis
    ¸¸¼º°£¿°
  • chronic persistent hepatitis
    ¸¸¼ºÁö¼Ó°£¿°
  • drug-induced hepatitis
    ¾à¹°À¯¹ß°£¿°
  • delta hepatitis
    µ¨Å¸°£¿°
  • epidemic hepatitis
    À¯Çà°£¿°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivated vaccine
    ºÒȰ¼ºÈ­¹é½Å, ºñµ¿È­¹é½Å
  • hepatitis
    °£¿°
  • acute hepatitis
    ±Þ¼º°£¿°
  • neonatal hepatitis
    ½Å»ý¾Æ°£¿°
  • serum hepatitis
    Ç÷û°£¿°
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivated serum
    ºñȰ¼ºÈ­Ç÷û
  • inactivated vaccine
    ºÒȰ¼ºÈ­¹é½Å, ºñµ¿È­¹é½Å
  • alcoholic hepatitis
    ¾ËÄڿ𣿰
  • amebic hepatitis
    ¾Æ¸Þ¹Ù°£¿°
  • anicteric hepatitis
    ¹«È²´Þ°£¿°
  • autoimmune hepatitis
    (¢¡chronic active hepatitis) ¸¸¼ºÈ°µ¿°£¿°
  • hepatitis B core antigen
    ºñÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    ºñÇü°£¿°Ç¥¸éÇ׿ø
  • cholangiolitic hepatitis
    (¢¡cholestatic hepatitis) ´ãÁóÁ¤Ã¼°£¿°
  • cholestatic hepatitis
    ´ãÁóÁ¤Ã¼°£¿°
  • chronic active hepatitis
    ¸¸¼ºÈ°µ¿°£¿°
  • chronic persistent hepatitis
    ¸¸¼ºÁö¼Ó°£¿°
  • delta hepatitis
    µðÇü°£¿°
  • drug-induced hepatitis
    ¾à¹°°£¿°
  • epidemic hepatitis
    À¯Ç༺°£¿°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivated serum
    ºñȰ¼ºÈ­Ç÷û.
  • inactivated vaccine
    ºñȰ¼ºÈ­¹é½Å.
  • inactivated vaccine
    ºñȰ¼ºÈ­¹é½Å.
  • inactivated vaccine
    ºñȰ¼ºÈ­¹é½Å.
  • HBc Ag => hepatitis B core antigen
    B Çü °£¿° c Ç׿ø
  • HBe Ag => hepatitis B e antigen
    B Çü °£¿° e Ç׿ø
  • HBsAg => hepatitis B surface antigen
    B Çü °£¿° s Ç׿ø
  • HDAg => hepatitis D antigen
    D Çü °£¿°Ç׿ø
  • Halothane hepatitis
    ÇÒ·Îź°£¿°
  • Hepatitis
    °£¿°(ÊÜæú)
  • Hepatitis B core antigen(HBc Ag)
    BÇü °£¿°ÇÙ½ÉÇ׿ø
  • acute hepatitis
    ±Þ¼º °£¿°
  • acute viral hepatitis
    ±Þ¼º ¹ÙÀÌ·¯½º°£¿°(¡­ÊÜæú).
  • acute viral hepatitis
    ±Þ¼º¹ÙÀÌ·¯½º¼º °£¿° (~ÊÜæú)
  • amebic hepatitis
    ¾Æ¸Þ¹Ù¼º °£¿°
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivated serum
    ºñȰ¼ºÈ­Ç÷û.
  • inactivated vaccine
    ºñȰ¼ºÈ­¹é½Å.
  • inactivated vaccine
    ºñȰ¼ºÈ­¹é½Å.
  • inactivated vaccine
    ºñȰ¼ºÈ­¹é½Å.
  • vaccine, inactivated virus
    ºÒȰ¼ºÈ­ ¹ÙÀÌ·¯½º ¹é½Å
  • acute hepatitis
    ±Þ¼º °£¿°
  • acute viral hepatitis
    ±Þ¼º¹ÙÀÌ·¯½º¼º °£¿° (~ÊÜæú)
  • acute viral hepatitis
    ±Þ¼º ¹ÙÀÌ·¯½º°£¿°(¡­ÊÜæú).
  • alcoholic hepatitis
    ¾ËÄڿüº °£¿°
  • alcoholic hepatitis
    ¾ËÄڿüº °£¿°(¡­àõÊÜæú)
  • amebic hepatitis
    ¾Æ¸Þ¹Ù¼º °£¿°
  • anicteric hepatitis
    ¹«È²´Þ¼º °£¿°.
  • antigen, hepatitis B core
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • antigen, hepatitis B surface
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • autoimmune hepatitis
    ÀÚ°¡¸é¿ª¼º °£¿°
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • amebic hepatitis
    ¾Æ¸Þ¹Ù°£¿°
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • inactivated vaccine
    ºÒȰ¼ºÈ­(ÝÕüÀàõûù) ¹é½Å
  • hepatitis B surface antigen
    BÇü(úþ) °£¿°(ÊÜæú) Ç¥¸é Ç׿ø(øúØüù÷ê«)
  • type A hepatitis
    AÇü(úþ) °£¿°(ÊÜæú)
  • type B hepatitis
    BÇü(úþ) °£¿°(ÊÜæú)
  • viral hepatitis
    ¹ÙÀÌ·¯½º¼º °£¿° (ÊÜæú)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • fulminant hepatitis
    Àü°Ý¼º°£¿°
  • hepatitis
    °£¿°
  • hepatitis B virus
    BÇü °£¿°¹ÙÀÌ·¯½º
  • infectious hepatitis virus
    Àü¿°¼º°£¿°¹ÙÀÌ·¯½º
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AH abdominal hysterectomy; absorptive hypercalciuria; accidental hypothermia; acetohexamide; acid hydro...
eIPV enhanced inactivated polio vaccine
HIFBS heat-inactivated fetal bovine serum
HIFCS heat-inactivated fetal calf serum
IFCS inactivated fetal calf serum
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
IPV Inactivated Polio-Vaccine
IPV Inactivated poliovirus vaccine
AIH 1)autoimmune hepatitis
AAH Acute alcoholic hepatitis
AH Acute hepatitis
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute hepatitis
    ±Þ¼º °£¿°
    ÀÌ º´¸íÀº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º¡¤½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀ̰í, °£µ¶¡¤È­Çоàǰ¡¤ÀǾàǰ µîÀ¸·Î »ý±â´Â Áßµ¶¼º °£¿°µµ ºñ±³Àû ¸¹´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༺ °£¿°
  • cholestatic hepatitis
    ´ãÁó ¿ïü¼º °£¿°, ´ãÁó Á¤Ã¼¼º °£¿°
  • chronic active hepatitis
    ¸¸¼º Ȱµ¿¼º °£¿°
  • chronic hepatitis B
    ¸¸¼º BÇü °£¿°
  • epidemic hepatitis
    À¯Ç༺ °£¿°
  • hepatitis
    °£¿°
    °£ÀÇ ¿°Áõ¼º Áúȯ. °£Àå¿°À̶ó°íµµ ÇÑ´Ù. °£ ÁúȯÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ´Â °ÍÀ¸·Î¼­, Å©°Ô ±Þ¼º °£¿°°ú ¸¸¼º °£¿°À¸·Î ³ª´«´Ù. ¡¼±Þ¼º °£¿°¡½ ÀÌ º´¸íÀº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º, ½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀ̰í, °£µ¶, È­ÇÐ ¾àǰ, ÀǾàǰ µîÀ¸·Î »ý±â´Â Áßµ¶¼º °£¿°µµ ºñ±³Àû ¸¹´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༺ °£¿°
  • hepatitis A
    AÇü °£¿°
    AÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÏ¿© ¹ß»ýÇÏ´Â Àü¼¼°èÀûÀ¸·Î ºÐÆ÷µÈ ÀÚ±â ÇÑÁ¤¼º ¹ÙÀÌ·¯½º¼º ÁúȯÀ¸·Î¼­, À§»ý »óŰ¡ ³ª»Ú°í °æÁ¦ ¼öÁØÀÌ ³·Àº Áö¿ª¿¡ ´õ¿í ¸¹ÀÌ ¹ß»ýÇÏ¸ç ºñ°æ±¸Àû °¨¿°µµ °¡´ÉÇϱâ´Â Çϳª °ÅÀÇ ÀüÀûÀ¸·Î ´ëº¯ °æ±¸ °æ·Î¸¦ ÅëÇÏ¿© ÀüÆÄµÇ°í, º¸±ÕÀÚ »óÅ´ »ý±âÁö ¾Ê´Â´Ù. Àẹ ±â°£Àº 15-20ÀϷμ­ Æò±Õ 30ÀÏÀÌ´Ù. ´ë´Ù¼ö ȯÀÚ´Â ÀÓ»ó Áõ¼¼°¡ ¶Ñ·ÇÇÏÁö ¾Ê°Å³ª °æÇÑ °¨±â Áõ»óÀ» ³ªÅ¸³»¸ç Ȳ´ÞÀº ÀÖ´õ¶óµµ ¸Å¿ì °æ¹ÌÇÏ´Ù. ±¤¹üÀ§ÇÑ °£ ±«»ç°¡ ÀϾ ¼ö ÀÖÀ¸³ª BÇü °£¿°¿¡¼­ º¸´Ù´Â ÈξÀ Àû°Ô ³ªÅ¸³­´Ù.
  • hepatitis B
    BÇü °£¿°
    BÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ °£ÀÇ ¿°Áõ¼º ÁúȯÀ¸·Î¼­ Àü¼¼°èÀûÀ¸·Î À¯ÇàÇϸç À¯ÇàÀÌ °¡Àå ³ôÀº Áö¿ªÀº Áß°î°ú µ¿³²¾Æ, »çÇ϶ó ÁÖº¯ ¾ÆÇÁ¸®Ä«, ÅÂÆò¾ç±ºµµÀÇ ´ëºÎºÐ ¹× ¾Æ¸¶Á¸ À¯¿ª µîÀÌ´Ù.
  • hepatitis B virus
    BÇü °£¿° ¹ÙÀÌ·¯½º
    1. BÇü °¨¿° ȯÀÚ¿¡¼­ ¸ðµç ü¾× ³»·Î ¹æÃâµÇ´Â ¹ÙÀÌ·¯½º. 2. »ç¶÷ÀÇ °£¿¡ »ì¸ç, Ç÷û °£¿° µîÀ» ÀÏÀ¸Å°´Â ¹ÙÀÌ·¯½º. HB ¹ÙÀÌ·¯½º¶ó°íµµ ÇÑ´Ù. HBs Ç׿ø, HBc Ç׿ø, HBe Ç׿ø µî ¼¼ Á¾·ùÀÇ Ç׿ø ´Ü¹éÁúÀ» Áö´Ñ ¹ÙÀÌ·¯½ºÀÌ´Ù. ÀÌ °¡¿îµ¥ HBs Ç׿ø¿¡´Â º¹¼öÀÇ Ç׿ø °áÁ¤±â°¡ ÀÖ¾î, ±× ¦¸ÂÃã¿¡ µû¶ó BÇü °£¿° ¹ÙÀÌ·¯½º´Â adr, adw, ayr, aywÀÇ 4°¡Áö ¾ÆÇüÀ¸·Î ³ª´©¾îÁ® ÀÖ´Ù. 1965³â ¹Ì±¹ÀÇ S. ºí·³¹ö±×°¡ ¿À½ºÆ®·¹Àϸ®¾Æ ¿øÁÖ¹ÎÀÇ Ç÷û¿¡¼­ ¹ß°ßÇÏ¿© ´çÃÊ¿¡´Â Ç׿ø¼ºÀÌ ÀÖ´Â ¹°ÁúÀ̶ó°í º¸°í, HB Ç׿ø ¶Ç´Â ¿À½ºÆ®·¹Àϸ®¾Æ Ç׿øÀ̶ó°í ºÒ·¶´Ù. ±× ÈÄ DNA
  • infectious hepatitis virus
    Àü¿°¼º °£¿° ¹ÙÀÌ·¯½º
  • lupoid hepatitis
    ·çÇÁ½º¾ç °£¿°, À¯³¶Ã¢ °£¿°
    ¼Ò±¸Áø»ó º´º¯À» Ư¡À¸·Î ÇÏ´Â À¯À°Á¾ÁõÀÇ °£¿°.
  • neonatal hepatitis
    ½Å»ý¾Æ °£¿°
  • serum hepatitis
    Ç÷û °£¿°
    ¹ÙÀÌ·¯½º¼º °£¿° Áß BÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÏ¿© °£ÀÌ Ä§ÇØµÇ´Â º´. Áõ¼¼´Â À¯Ç༺ °£¿°°ú º»ÁúÀûÀ¸·Î´Â ´Ù¸¦ ¹Ù°¡ ¾ø´Ù. ´Ù¼Ò ¿Ï¸¸ÇÏ°Ô ½ÃÀÛµÇÁö¸¸ °æ°ú°¡ ±æ°í, ¸¸¼ºÈ­ÀÇ °æÇâµµ °­ÇÏ´Ù. Àẹ±â´Â 60¡­90ÀÏÀε¥, ¼öÇ÷ ÈÄ 20ÀÏ Á¤µµ·Î ³ªÅ¸³ª´Â ¼öµµ ÀÖ´Ù. °¨¿° °æ·Î´Â Ç÷¾× ¹× Ç÷¾×Á¦Á¦
  • viral hepatitis
    ¹ÙÀÌ·¯½º °£¿°, ¹ÙÀÌ·¯½º¼º °£¿°
    ÃÖ¼Ò 5Á¾ÀÇ ¼­·Î ´Ù¸¥ ¹ÙÀÌ·¯½º°¡ ¿øÀÎÀÌ µÇ¸ç ÀÌµé ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î ÀÎÇÑ °£¿°.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
vaccines, inactivated Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
(12 Dec 1998)
inactivated polio vaccine <pharmacology, virology> An inactivated vaccination, administered by injection to children for protection against the polio virus. Typically given at 2, 4 and 15 months. A final vaccine is recommended at 4-6 years.
(27 Sep 1997)
inactivated poliovirus vaccine Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine.
See: Salk vaccine.
(05 Mar 2000)
inactivated serum <immunology> Serum that has been heated 50°C for 30 minutes to destroy the lytic activity of complement.
(05 Mar 2000)
acute parenchymatous hepatitis A lesion in which there is extensive and rapid death of parenchymal cells of the liver, sometimes with fatty degeneration of the size of the organ; the necrosis may result from fulminant viral infection or chemical poisoning; associated with jaundice.
Synonym: acute parenchymatous hepatitis, Rokitansky's disease.
(05 Mar 2000)
anicteric hepatitis Hepatitis without jaundice.
(05 Mar 2000)
anicteric virus hepatitis A relatively mild hepatitis, without jaundice, due to a virus; the principal physical signs and symptoms are enlargement of the liver, lymph nodes, and often the spleen, together with headache, continuous fatigue, nausea, anorexia, sudden distaste for smoking, abdominal pains, and sometimes mild fever; labratory tests reveal evidence of hepatitis.
(05 Mar 2000)
autoimmune hepatitis <pathology> A type of chronic active hepatitis that results from circulating auto-antibodies and chronic inflammation of the liver.
Symptoms are those of chronic active hepatitis.
(27 Sep 1997)
vaccination, hepatitis a When immediate protection against hepatitis a (infectious hepatitis) is needed, immunoglobulins are used. Protection is effective only if given within 2 weeks of exposure and lasts but 2-4 months. Immunoglobulins can be used to protect household contacts of someone with acute viral hepatitis and travelers to regions with poor sanitation and high hepatitis a rates, when the traveler has to depart sooner than the vaccines can take effect (about 2 weeks). Travelers can receive the immunoglobulin and vaccine simultaneously and be protected immediately and for longer term. When immediate protection is not needed, hepatitis a vaccines are considered for individuals in high-risk settings, including frequent world travelers, sexually active individuals with multiple partners, homosexual men, individuals using illicit drugs, employees of daycare centres, and certain health care workers, and sewage workers. Two hepatitis a vaccines called havrix and vaqta are commercially available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection.
(12 Dec 1998)
vaccination, hepatitis b Hepatits B (hep B) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are available in the u.s. Both are highly effective and provide protection even after only one dose. Two doses are recommended for adults and 3 doses for children (under 18 years of age) to provide prolonged protection. Vaccination, hepatitis b: hepatits b (hep b) vaccine gives prolonged protection, but 3 shots over a half year are usually required. In the u.s., all infants receive hep b vaccine. Two vaccines (engerix-b, and recombivax-hb) are available in the us. The first dose of hep b vaccine is frequently given while the newborn is in the hospital or at the first doctor visit following birth. The second dose is given about 30 days after the initial dose. A booster dose is performed approximately six months later. Babies born to mothers testing positive for hep b receive, in addition, hbig (hep b immune globulin) for prompt protection. Older children (11-12 years) are advised to receive a hep b booster as are adults in high-risk situations including healthcare workers, dentists, intimate and household contacts of patients with chronic hep b infection, male homosexuals, individuals with multiple sexual partners, dialysis patients, iv drug users, and recipients of repeated transfusions. Health care workers accidentally exposed to materials infected with hep b (such as needle sticks), and individuals with known sexual contact with hep b patients are usually given both hbig and vaccine to provide immediate and long term protection.
(12 Dec 1998)
vaccination, infectious hepatitis See Vaccination, hepatitis a.
(12 Dec 1998)
vaccineation, serum hepatitis See Vaccination, hepatitis b.
(12 Dec 1998)
giant cell hepatitis Hepatitis in the neonatal period presumed to be due to a variety of causes, chiefly viral; characterised by direct and indirect bilirubinaemia, hepatocellular degeneration, and appearance of multinucleated giant cells; may be difficult to distinguish from biliary atresia, but is more likely to end with recovery, although cirrhosis may develop.
Synonym: giant cell hepatitis.
(05 Mar 2000)
viral hepatitis Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses can also cause hepatitis, their primary target is not the liver.
(12 Dec 1998)
viral hepatitis type A A virus disease with a short incubation period (usually 15 to 50 days), caused by hepatitis A virus, a member of the family Picornaviridae, often transmitted by faecal-oral route; may be inapparent, mild, severe, or occasionally fatal and occurs sporadically or in epidemics, commonly in school-age children and young adults; necrosis of periportal liver cells with lymphocytic and plasma cell infiltration is characteristic and jaundice is a common symptom.
Synonym: epidemic hepatitis, hepatitis A, infectious hepatitis, MS-1 hepatitis, short incubation hepatitis, virus A hepatitis.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hepatitis
    °£¿°
  • hepatitis A
    AÇü °£¿°;Àü¿°¼º(Ç÷û)°£¿°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á